Kristie L. Kahl: Can you explain what smoldering myeloma is? Dr. Irene Ghobrial: Many patients come in to see us because they have back pain or anemia or kidney problems; however, if we know that ...

A recent phase 3 trial is exploring the question of whether or not smoldering multiple myeloma needs treatment. Do patients with smoldering multiple myeloma require treatment? That is the question ...

Multiple myeloma is a type of blood cancer caused by a buildup of abnormal plasma cells in the bone marrow. As the abnormal plasma cells accumulate, they crowd out healthy cells and cause symptoms ...

A potential first-ever FDA-approved treatment for smoldering myeloma received a positive review from an advisory committee, but not without reservations, even from panelists who voted in favor. By a 6 ...

Treating high-risk smoldering multiple myeloma with single-agent daratumumab (Darzalex) delayed progression to active myeloma, according to findings from the phase III AQUILA trial presented at the ...

The terminology for smoldering myeloma has been around for decades, but more discussion over what it means and who it really applies to is needed, said C. Ola Landgren, MD, PhD, professor of medicine ...

Please provide your email address to receive an email when new articles are posted on . Daratumumab delayed progression of smoldering multiple myeloma compared with active monitoring. Among those who ...

Open in Viewer Table 2. Risk Stratification Models for Smoldering Multiple Myeloma To address the updated definition of SMM, the Mayo group revised their risk stratification (Table 2). 21 They ...

Patients with multiple myeloma (MM) face higher risks of certain metabolic syndromes, but new research suggests those risks exist even in patients with smoldering MM. It has long been understood that ...

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study We used next-generation ...

Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...